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Abstract 
A standardized test for the serodiagnosis of human cystic echinococcosis (CE) is still 
needed, because of the low specificity and sensitivity of the currently available 
commercial tools and the lack of proper evaluation of the existing recombinant antigens. 
In a previous work, we defined the new ELISA-B2t diagnostic tool for the detection of 
specific IgGs in CE patients, which showed high sensitivity and specificity, and was 
useful in monitoring the clinical evolution of surgically treated CE patients. 
Nevertheless, this recombinant antigen gave rise to false-negative results in a percentage 
of CE patients. Therefore, in an attempt to improve its sensitivity, we constructed B2t-
derived recombinant antigens with two, four and eight tandem repeat of B2t units, and 
tested them by ELISA on serum samples of CE patients and patients with related 
parasites. The best diagnostic values were obtained with the two tandem repeat 2B2t 
antigen. The influence of several clinical variables on the performance of the tests was 
also evaluated. Finally, the diagnostic performance of the 2B2t-ELISA was compared 
with that of an indirect haemagglutination commercial test. The 2B2t recombinant 
antigen performed better than the HF and B2t antigens, and the IHA commercial kit. 
Therefore, this new 2B2t-ELISA is a promising candidate test for the serodiagnosis of 
CE in clinical settings. 
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Author summary 
Cystic echinococcosis (CE) is a widespread zoonotic disease. Its complex clinical 
presentation precludes a “one-size-fits-all” approach to clinical management, 
particularly with regard to serodiagnosis. While CE is often detected incidentally by 
imaging, imaging findings may be inconclusive. Therefore, there is a need for 
standardised and approachable diagnostic tools that may complement imaging data. In 
this regard, serological tests based in the use of native antigens like hydatid fluid present 
a low specificity and sensitivity. Although recombinant antigens with potential to 
replace native antigens have been proposed in the literature, none has been 
systematically tested for diagnostic performance. Here, we describe the new 
recombinant antigen 2B2t, derived from the previously described recombinant B2t, and 
determine its usefulness for the serodiagnosis of CE by ELISA in patients with a 
complete set of clinical data. The influence of clinical variables on the performance of 
2B2t was evaluated and compared with the hydatid fluid (the most commonly used 
antigen for CE serology) and a commercial diagnostic kit based on the 
haemagglutination reaction. Our results show that the 2B2t antigen has potential to be 
routinely used for the standardised diagnosis of CE in clinical settings. 
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Introduction 
Cystic echinococcosis (CE) is a zoonosis caused by the metacestode of Echinococcus 
granulosus. In Europe, this cestode is more commonly found in Mediterranean 
countries, where it is usually maintained through a domestic life cycle involving dogs 
and sheep [1-2]. CE is still a cause for concern in many European countries [3]. It is 
also a major problem in developing countries, where it carries significant morbidity and 
mortality in both humans and animals [4-5]. 
CE diagnosis is mostly based on imaging techniques and can be facilitated by using the 
WHO international classification of ultrasound images in CE [6]. This classification is 
also useful in determining the type of cyst according to its activity (i.e., active: CE1, 
CE2; transitional: CE3a, CE3b; or inactive: CE4, CE5), and to monitor the clinical 
evolution of patients. Most importantly, the classification was recently validated by a 
study that used Magnetic Resonance Spectroscopy to investigate the metabolic profiles 
of the different cyst stages [7]. Laboratory and imaging data are usually sufficient to 
establish a reliable diagnosis but sometimes they are inconclusive [8]. An immunoassay 
can be used as a confirmatory test, and usually consists of an E. granulosus hydatid 
fluid (HF) antigen ELISA [8]. The sensitivity of the HF-ELISA for the diagnosis of 
different cases of CE ranges between 50 and 98%, and depends on the localization, size, 
number and stage of cysts. Several other factors, such as the time between initiation of 
treatment onset and the date of serum collection, CE antecedents (patients suffering of a 
previous CE), and the presence of complications, could also affect the results of the 
tests. This may explain the great variability in the sensitivity reported by different 
laboratories using the same antigen (HF or recombinant antigens) [9]. However, in most 
articles published in the field, data on these variables were not reported, which 
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prevented the development of a routine serodiagnostic tool with a consistent and 
clinically acceptable diagnostic performance. 
Several recombinant antigens have shown potential for CE serodiagnosis [9]. In this 
regard, we recently proposed the use of a C-terminal truncated recombinant antigen B2 
(B2t) for the diagnosis and monitoring of CE patients by ELISA. Indeed, this B2t-
ELISA showed excellent diagnostic accuracy (91.2% sensitivity and 93% specificity), 
and had the potential to signal cure in surgically treated CE patients [10]. This study 
was performed on CE patients with no indication of the above-mentioned variables, 
except for cyst localization. 
Several studies, such as the recent one by Valiente-Gabioud et al. [11] on a specific 
Trypanosoma cruzi antigen, showed that an increase in the number of repetitive units of 
an antigen could result in an enhanced antigenic response. Because the use of the B2t 
antigen gave rise to some false-negative results, we thought to use the same antigen, but 
with a variable number of tandem repeats. Therefore, we collected sera from several CE 
patients, as well as complete information on the variables listed above with the potential 
to affect the results of the tests. The capacity of the recombinant antigens obtained to 
diagnose CE was assessed by ELISA and compared with each other and with the HF 
antigen. Finally, the diagnostic performance of the new antigens was compared to that 
of their corresponding commercial indirect haemagglutination (IHA) kit, using serum 
from the same CE patients. 
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Methods 
Antigens 
Crude sheep HF collected from fertile hydatid cysts and containing viable protoscoleces 
was kindly provided by S. Jiménez (Servicio de Seguridad Alimentaria y Sanidad 
Ambiental, Consejería de Salud de La Rioja, Spain). The HF was centrifuged at 1,000g 
for 5 min, and the protein concentration in the supernatant was measured with the Micro 
BCA Protein Assay Kit (Pierce). The supernatant was then stored at -80°C until use. 
The B2t recombinant antigen was obtained as described before [10]. Briefly, the coding 
sequence of antigen B2 (GenBank entry number U15001) was cloned in the pGEX-4T2 
expression vector, excluding the region coding for the signal peptide (GE Healthcare 
Life Sciences). This construct was then used to transform BL21-CodonPlus-RIL 
competent cells, derivative of Escherichia coli (Stratagene). Protein expression and 
purification were carried out as described before [10]. 
Three molecules with a variable number of tandem repeats (2B2t, 4B2t and 8B2t 
containing two, four and eight B2t subunits, respectively) were synthesised based on the 
original B2t recombinant antigen, as described before [12], albeit with minor 
modifications. Briefly, a pair of PCR primers spanning the whole B2t-pGEX-4T2 
sequence (except for the terminal codon) were designed. They also included restriction 
sites for BglII and BamHI in the 5’- and 3’-ends, respectively, which are marked in 
italics in the following sequences:  forward primer 5’- 
ACAGATCTAAAGATGAGCCAAAAGC and reverse primer 5’- 
ATGGATCCCTTTGAATCATCATC. The PCR was carried out in a Techne T-512 
termocycler, for 35 cycles. The five first cycles consisted of 40 sec at 94ºC, 40 sec at 
48ºC and 1 min at 72ºC, and the next 30 cycles consisted of 40 sec at 94ºC, 40 sec at 
58ºC and 1 min at 72ºC. The PCR product was then purified with the Strataprep DNA 
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Gel Extraction Kit (Stratagene) and inserted into the pGEM-T Easy vector (Promega), 
which contains a restriction site for SacI, downstream of the cloning site. Subsequently, 
the recombinant vector was subjected to two double digestions in parallel, one with 
BamHI and SacI, resulting in the linearisation of the construct, and another one with 
BglII and SacI, to obtain the fragment corresponding to the B2t coding sequence. Both 
products were then ligated, which led to the ligation of the BglII and BamHI restriction 
sites, and resulted in the loss of the restriction sites ligating the 2B2t molecules. This 
step was repeated to obtain the 4B2t and 8B2t molecules. The resulting tandem repeat 
constructs of 446, 874 and 1,738 base pairs, respectively, were sequenced to check for 
ligations and open reading frames. The three constructs were then excised from the 
pGEM-T Easy vector with EcoRI and subcloned in the pGEX-4T1 expression vector. 
Expression and purification of the corresponding proteins was performed as described 
before [10]. The purity and yield of each protein obtained after purification and 
thrombin cleavage of the respective GST-fused proteins were assessed in 12% 
polyacrylamide gels using Coomasie blue staining. The densitometry was calculated 
with the ImageJ software (http://rsbweb.nih.gov/ij/). 
 
Ethics statement 
For this study, the serum of CE patients and healthy donors was used (see next section). 
The study was approved by the ethics committees of the University Hospitals of 
Salamanca and Valladolid, Spain, and the main IRB of Cayetano Heredia University of 
Lima, Peru. 
All subjects gave their informed written consent, which specified that these samples 
could be used for future analyses. 
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Serum 
103 Spanish sera were used to test the diagnostic value of the three tandem repeat B2t 
recombinant proteins, and to compare it to that obtained with the original B2t and HF 
antigens. The individuals comprised 49 healthy donors and 54 patients with surgically 
confirmed CE, selected for their previously known reactivity to the B2t recombinant 
antigen by ELISA (12 B2t-negative and 42 B2t-positive; unpublished data). 
Further characterization of the recombinant B2t and 2B2t antigens was performed using 
the serum of 186 Peruvian patients with CE confirmed surgically and/or by imaging. 
The clinical characteristics of the patients are presented in Table 1. They were recruited 
in the INPACCE (Lima, Peru) from 2007 to 2008, if they had clinical findings 
compatible with CE and were living in endemic (34%) and non-endemic (66%) areas 
for CE. Additionally, the serum of 110 healthy donors, 36 patients with hepatitis (both 
groups recruited in the Hospital of Salamanca, Spain) and 138 patients with related 
parasites confirmed by microscopy or specific ELISA or immunoblot assay (70 patients 
with neurocysticercosis, including 57 Peruvian patients with neurological symptoms 
and living in endemic areas for cysticercosis recruited in the Institute for Neurological 
Science (Lima, Peru) in 2007 and 13 Mexican patients; 57 Swiss patients with alveolar 
echinococcosis; and 11 Peruvian patients with taeniosis) were tested. 
 
Enzyme-linked immunosorbent assay (ELISA) and indirect haemagglutination test 
(IHA) 
The sera and antigens were tested by IgG ELISA, as described before [10]. Briefly, 96-
well polystyrene plates (Corning, Madrid, Spain) were coated overnight at 4ºC with the 
B2t, 2B2t, 4B2t or 8B2t recombinant proteins (0.5 μg/ml) or with HF (5 μg/ml) in 
carbonate buffer, pH 9.6 (100 l/well). The plates were then washed six times with 
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phosphate buffered saline (PBS, pH 7.4) plus 0.05% Tween 20 (washing buffer) and 
incubated for 1.5 h at 37°C with 200 μl of washing buffer plus 1% bovine serum 
albumin (BSA; Sigma Aldrich, Madrid, Spain) (blocking buffer). Then, the sera were 
added in duplicate (100 μl/well) at 1:200 dilution in blocking buffer, and the plates were 
incubated for 1 h at 37°C. The plates were washed again, and the secondary antibody 
(peroxidase-labelled rabbit anti-human IgG; Sigma Aldrich, Madrid, Spain) was added 
at a 1:2000 dilution in blocking buffer (100 μl/well), and incubated for 1 h at 37°C. 
After washing, the plates were stained with 100 μl/well of citrate buffer pH 5 plus 
orthophenylene diamine (0.28 mg/ml; Sigma Aldrich, Madrid, Spain) and hydrogen 
peroxide (0.4 μl/ml; Sigma Aldrich, Madrid, Spain). The reaction was stopped with 50 
μl/well of 3 N sulfuric acid, and the plates were read at 492 nm with an ELISA reader 
instrument (STL 340 ATC reader, Lab Instruments, Salzburg, Germany). 
The IHA kit (Hydatidose Fumouze Kit, Fumouze Diagnostics, Levallois-Perret, France) 
was applied to the above-mentioned sera, according to the manufacturer’s instructions. 
Briefly, the sera were diluted at 1:40 in the serum diluter from the kit. This solution was 
used to obtain two-fold serial dilutions of each serum, as indicated by the supplier, in 
round-bottom plates. Then, a drop of sensitized red cells was added to each well, and 
the plates were incubated at room temperature for two hours. Subsequently, the 
agglutination reactions were interpreted according to the manufacturer’s instructions. 
Thus, the sera were considered positive when agglutination was observed at ≥ 1:320 
dilutions (cut-off value of 1:320). An agglutinin control was performed for several 
randomly selected sera, as recommended by the manufacturer. 
 
Statistics 
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The serological activity index was calculated for each optical density and used to 
establish a common cut-off value for all the ELISAs performed for each antigen, using 
the following formula: [(NC - S)/(NC -PC)]*100, where NC and PC are the negative 
and positive controls, respectively, and S stands for each serum. The best cut-off value 
was then determined by receiver operator characteristic (ROC) analysis for each 
antigen. For the determination of that value, sera from the 186 Peruvian CE patients 
were considered true positive and 110 sera from donors plus 174 sera from patients with 
other diseases were considered true negative. 
A chi-square test was used to compare the sensitivity of the B2t, 2B2t and HF antigens 
for the detection of total IgG by ELISA, in groups of CE patients with different clinical 
and cyst-related characteristics, which could influence the resulting sensitivity. A P 
value <0.05 was considered statistically significant. Additionally, two different 
statistical approaches were used to evaluate the influence of the different clinical 
variables on the diagnostic performance of the different tests. First, a bivariate binary 
logistic regression was performed to calculate the odd ratio (OR) for each pair of 
clinical variables, and identify those associated with test performance. Then, the 
significant variables were further analysed by multivariate binary logistic regression, to 
identify those independently associated with the performance of each serological test, 
taking into account the simultaneous participation of the other variables. All statistical 
analyses were performed with SPSS v.19 (www.ibm.com). 
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Results 
Recombinant antigens 
The tandem ligation of the B2t nucleic acid sequence of 213 base pairs (bp) resulted in 
three products of 446, 874 and 1,738 bp, corresponding to the 2B2t, 4B2t and 8B2t 
antigens, respectively (Figure 1A). The B2t, 2B2t, 4B2t and 8B2t recombinant proteins 
were obtained as described previously [10], by thrombin cleavage of the respective 
GST-fused products, resulting in polypeptides with molecular weights of 8.3, 16.9, 31.3 
and 60.1 kDa, as expected, and with high purity and no degradation (Figure 1B). After 
purification (Fig. 1B), the highest yield was obtained for the 2B2t, followed by 4B2t, 
B2t and 8B2t proteins. The production of the 8B2t protein was too low and was 
therefore disregarded. 
The 2B2t recombinant antigen was patented (P201030983). 
 
Usefulness of the B2t-derived recombinant antigens for the serodiagnosis of CE. 
Comparison with a commercial IHA kit. 
The preliminary assessment of the diagnostic performance of the recombinant B2t, 2B2t 
and 4B2t proteins ELISA was performed using the serum of 49 healthy donors and 54 
patients with confirmed CE, selected for their previously known reactivity to the B2t 
recombinant antigen. As shown in Table 2, the highest sensitivity was obtained with the 
2B2t antigen (92.6%), followed by the HF (81.5%) and the 4B2t antigens (79.6%). Both 
the 2B2t and 4B2t antigens showed a higher sensitivity than the B2t antigen in this 
analysis (77.8% sensitivity). The specificity obtained in the serum of the 49 healthy 
donors with the 4B2t antigen was only of 79.6%, and was thus lower than the specificity 
obtained with the HF (93.9%) and the two other recombinant antigens (95.9%). The 
difference in sensitivity observed between the 2B2t antigen and the HF, B2t and 4B2t 
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antigens was statistically significant in each case. However, the difference in specificity 
was only statistically significant when comparing the 2B2t antigen with the 4B2t 
antigen (see Table 2). 
Because of its low specificity, the 4B2t antigen was discarded from further studies, and 
the subsequent analyses thus focused on the B2t and 2B2t antigens. 
Then, the serum of 186 Peruvian patients with confirmed CE, 110 healthy donors and 
174 patients with different infectious diseases was used to compare the usefulness of the 
2B2t recombinant antigen with that of the B2t and HF antigens by ELISA and by IHA 
with a commercial kit (Fumouze Diagnostics, Levallois-Perret, France), based on the 
detection of specific serum antibodies against a purified fraction of the E. granulosus 
antigen 5. 
The results obtained with the 186 Peruvian CE patients are shown in Table 3, 
specifically sensitivities of 83.3%, 79% and 87.6% for the HF, B2t and 2B2t antigens, 
respectively, and of 34.9% were found when using the IHA kit. For the 2B2t-ELISA, 
only 5.9% of the sera from CE patients was close (± 5 SI units) to its cut-off value. The 
difference in sensitivity between the 2B2t-ELISA and each of the other three tests was 
statistically significant. The evaluation of the four diagnostic tools using serum from 
healthy donors showed that the IHA was the most specific test, followed by the B2t- 
and 2B2t-ELISA, and the HF-ELISA (Table 3). The difference between the 2B2t-
ELISA and HF-ELISA was statistically significant. The most significant cross-
reactivity was detected in NCC Peruvian patients for the 2B2t antigen, although two of 
them also showed a positive immunoblot against HF (data not shown), suggesting that 
they could actually suffer from CE. Strikingly, no cross-reactivity was noted with the 
2B2t-ELISA in 13 NCC Mexican patients (Table 3). The difference in cross-reactivity 
was statistically significant between the 2B2t-ELISA and each of the other three tests. 
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Several variables that could potentially affect the sensitivity of the tests with the 
different in-house antigens and the commercial IHA kit were analysed. These variables 
included the number of cysts (one or more), localization (liver or lung), WHO 
ultrasound classification (liver cysts were grouped into two subgroups, i.e., CE1, and 
CE2 to CE4, to have a representative number of cases in each subgroup), CE 
complications (ruptured cyst, in 51 patients, or infected cyst, in 47 patients), CE 
antecedents and date of serum collection vs. date of treatment onset (of the 57 patients 
whose serum was collected after treatment onset, 55 were surgically treated and two 
were only treated with albendazole). First, a chi squared test was used to calculate the 
sensitivity of the tests for each variable, without considering the potential influence of 
the others. The results from this analysis are shown in Table 4. The sensitivity of the 
test with the HF antigen was shown to be affected by a higher number of variables as 
compared to the recombinant antigens, including the number of cysts and their 
localisation and classification, CE antecedents, complications and the collection of 
serum before or after treatment. Similarly, the results obtained with the IHA kit were 
affected by all variables, except for CE antecedents. The sensitivity of the test with the 
B2t antigen was affected by the number of cysts and the date of serum collection. 
Indeed, the screening of patients with a single cyst was more frequently negative than 
that of patients with more multiple cysts, and serum collection after treatment was 
associated with an increased probability of presenting a positive result by B2t-ELISA. 
The performance of the 2B2t recombinant protein was only affected by one variable 
(the number of cysts), and showed a lower number of positive results in patients with a 
single cyst than in those with multiple cysts (P<0.05). The time of serum collection, i.e., 
before or after surgical treatment, which affected the performance of the test using the 
B2t antigen, did not affect the performance of the test using the 2B2t antigen. However, 
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the influence of other treatments should be further investigated. A higher number of 
positive patients was consistently detected with the 2B2t than with the HF or B2t 
antigens in all groups. 
The influence of complications was also assessed by separating the complicated group 
into two subgroups, i.e., those with ruptured cysts or infected cysts. Among the 98 
patients with complications, 51 (52%) had ruptured cysts and 47 (48%) had infected 
cysts. The difference in the number of positive results between the two subgroups was 
not statistically significant for any of the antigens tested (data not shown). 
The results of the bivariate analysis, which was used to compare the results obtained 
with each test and to assess the influence of different clinical variables are shown in 
Table 5. The IHA test was the one affected by the highest number of variables. Indeed, 
the presence of more than one cyst, of complications, of cysts in the lungs, and serum 
collection after treatment were significantly associated with a higher probability of 
positive result with the IHA test. This higher probability was also observed by 
multivariate analysis (P<0.05; Table 5). On the other hand, CE2 to CE4 cysts, CE 
complications and serum collection after treatment were significantly associated with a 
higher probability of positive result with the HF-ELISA. These associations were 
maintained in the multivariate analysis (P<0.05; Table 5). Regarding the recombinant 
antigens, a higher probability of positive result was noted in the presence of multiple 
cysts (for B2t and 2B2t) and serum collection after treatment (for B2t; Table 5). 
However, only the presence of multiple cysts remained statistically significant in the 
multivariate analysis for B2t (P<0.05), but not serum collection after treatment 
(P=0.053). In addition, the presence of multiple cysts was not associated with a higher 
probability of positive result with 2B2t (P=0.064). 
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Discussion 
Our findings show that the new 2B2t-ELISA performs better than that of the HF- and 
B2t-ELISA, and also than that of a commercial haemagglutination test. As both the in-
house HF-ELISA and the IHA commercial kit are frequently used for the serodiagnosis 
of CE patients in clinical settings, the 2B2t-ELISA could represent a good alternative as 
a routine test for CE serology. 
The previously described B2t recombinant antigen [10] was used as the base for 
constructing the three tandem repeat antigens constituted by two, four and eight 
subunits. This approach was chosen based on the results of other studies showing an 
increase in antigenicity when two or more subunits of a specific antigen were cloned 
together and used for the diagnosis of specific diseases (e.g., leishmaniasis and 
trypanosomiasis) [11,13]. This increase in reactivity correlated with the increase in 
number of repeats in the recombinant proteins studied, and that was also shown here for 
the 2B2t antigen compared with the B2t antigen. In the present study, surprisingly, the 
4B2t antigen was revealed to be less reactive than the recombinant 2B2t antigen, 
although the latter contained a lower number of B2t subunits than the 4B2t antigen. This 
could be due to a conformation of the 4B2t protein unfavourable for antibody binding, 
compared to that of the 2B2t antigen. Indeed, the three-dimensional structure could have 
resulted in the loss of some conformational epitopes needed for antibody binding. 
The higher number of antigenic units also resulted in a lower specificity for the 4B2t-
ELISA, which presented a high number of false-positive results in healthy donors than 
the B2t-ELISA, while the 2B2t-ELISA showed the same specificity than the B2t-
ELISA. This loss of specificity associated with the increase in the number of antigenic 
repeat units has been shown before for other recombinant antigens (e.g., [13]). The 
cross-reactivity of the 2B2t antigen increased more markedly, as compared to that of the 
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B2t antigen when using serum from Peruvian patients with NCC. The western blot 
against 8, 16 and 21 kDa HF antigens was only positive in one of the cross-reactive 
Peruvian patients, and no correlation was found between a higher number of positive 
bands in the NCC-specific western blot and 2B2t cross-reactivity. Nevertheless, the 
absence of cross-reactivity in NCC patients from Mexico seemed to indicate the 
potential presence of true anti-E. granulosus antibodies in the NCC Peruvian samples. 
This could be explained by higher human prevalence of CE (5.5-9.1% in endemic 
villages) [14], than in Mexico. In fact, autochthonous Mexican CE cases are regarded as 
rare [15]. Because the serum donors were recruited in an area with a low endemicity for 
CE (Salamanca, Spain), the potential cross-reactivity detected in Peruvian patients 
should be further investigated with a panel of donors from the same area as the NCC 
patients. 
The commercial IHA kit proved to be highly specific, but a high cross-reactivity was 
detected with the serum from AE patients. The cross-reactivity of antigens usually used 
for the serodiagnosis of CE with alveolar echinococcosis (AE) is a serious drawback for 
the specific diagnosis of CE in areas where both parasites co-exist [8, 9]. In this regard, 
the ability of the new 2B2t antigen to discriminate between patients with CE and AE is 
very interesting. 
In spite of the higher sensitivity of the 2B2t-ELISA, which was the best of the four tests 
assessed here, a percentage of CE confirmed that patients from our cohort still showed 
negative results with the 2B2t-ELISA. Frequently, studies intending to validate 
serodiagnostic tools for CE fail to consider several clinical variables that could affect 
the diagnostic performance of these tools. In addition, serum selection is sometimes 
based on previous serologic information. As a consequence, divergent results are 
reported for the same test, e.g., ranging from 45 to 93% with the same recombinant 
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antigen B2 in IgG-ELISA [9]. False-negative results could then be due to clinical 
features influencing the level of specific circulating antibodies against defined antigens 
[4]. This has been shown for several variables; among them, the date of serum 
collection (relative to treatment initiation), as both pharmaceutical and surgical 
treatments can lead to a rise in the level of specific antibodies (e.g., [16]), the cyst stage 
(e.g., [17]), cyst localization (e.g., [18]) and the number of cysts (e.g., [19, 20]). 
Here, we examined the influence of six different clinical variables on the performance 
of the tests: the number of cysts, cyst localization, cyst stage, the presence of 
complications, CE antecedents, and date of serum collection (compared to that of 
treatment onset). Regarding cyst classification, because the number of samples in our 
study for some types of cysts was too low for statistical analysis (44 patients with CE1, 
22 patients with CE2, eight patients with CE3 and two patients with CE4), especially 
those belonging to the inactive (CE4-CE5) group, we could not group our patients into 
active, transitional and inactive groups in the attempt to relate cyst activity with the 
corresponding serological result. In this regard, the shift from active to inactive cysts 
has been shown to result in a decline of specific antibodies against the recombinant 
antigen B (e.g., [21]). Also related to this, the expression of the antigen B2 subunit has 
been shown to reduce with the senescence of cysts [22]. Therefore, we are aware that 
the performance of our antigens should be further investigated in a larger group 
including a higher number of patients with CE3, CE4 and CE5 cysts, preferably in a 
prospective follow-up trial. Nevertheless, CE1 cysts have also been shown to be more 
frequently associated with a seronegative response against parasite antigens, including 
antigen B, in contrast with the CE2 and CE3 types of cysts that are usually associated 
with a detectable and specific antibody response (e.g., [17, 21]). Thus, we decided to 
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group our patients into two groups: CE1 and CE2 to CE4, and determine if the results of 
the tests depended on this variable. 
All variables studied here (except one) influenced the sensitivity of the HF-ELISA, as 
observed by chi squared analysis. A very similar result was noted with the IHA 
commercial test. The B2t-ELISA was influenced by the number of cysts and date of 
serum collection (compared to that of treatment onset), while the 2B2t-ELISA was only 
influenced by the number of cysts. 
Strikingly, patients with cysts in the lungs were more frequently positive with the IHA 
kit and HF-ELISA than patients with cysts in the liver. This contradicts the reports of 
other authors, who showed that cysts in the lungs usually result in a lower antigenic 
stimulation than cysts in the liver (e.g., [18]). Nevertheless, these differences could be 
attributed to the influence of other clinical variables. In our group of patients, 66% of 
cysts in the lungs led to complications, compared to 27% for cysts in the liver, in both 
localizations at 1:1 proportion regarding ruptured and infected cysts. Then, the presence 
of complicated cysts could specifically account for a higher seropositivity influencing 
the test results, as noted with the IHA kit and HF-ELISA. These observations prompted 
us to perform a multivariate statistical analysis to assess the influence of all variables 
together. 
The results of the logistic regression indicated that four and three of six variables 
affected the outcome of the IHA kit and HF-ELISA, respectively, in association or not 
with the other variables. The results of the B2t-ELISA were influenced by the number 
of cysts. Thus, a patient with a single cyst is more likely to test negative at B2t than a 
patient with multiple cysts. On the other hand, the performance of the 2B2t-ELISA was 
statistically independent from all the clinical variables evaluated. Thus, the percentage 
of negative patients with a confirmed CE could be attributed to the absence of specific 
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antibodies associated with variables not evaluated in this study, either clinical or other, 
e.g., the formation of immune complexes. 
Nevertheless, although the better sensitivity of the 2B2t antigen over that of B2t 
resulted in a loss of statistically significant difference for some clinical variables, we are 
aware that the inclusion of a higher number of patients could result in a statistically 
significant association for some of the variables tested, especially for those showing a 
broad 95% confidence interval. Thus, our results suggest that multiple cysts, 
localisation in the liver vs. the lung, CE2 and CE3 cysts or complications, and serum 
collection after treatment onset are variables that increase the probability of a positive 
result with the 2B2t-ELISA. 
Considering the patients who tested negative with the 2B2t-ELISA (n=23), 78% had a 
single cyst, 65% had cysts in the lungs, 62.5% had CE1 types of cysts, 56% suffered 
from complications, and 78% provided a sample before initiation of the treatment. 
Unfortunately, the number of patients with negative serology was too low to draw any 
significant conclusion. Nevertheless, we could assume that a patient with an ultrasound 
image suggestive of CE, but presenting a single CE1 uncomplicated cyst located in the 
lungs, and whose was taken prior to the administration of any treatment, would 
probably yield a false-negative result with the 2B2t-ELISA. 
A striking example of how the results of a given test can change depending on the 
characteristics of a patient, was shown in the high difference in specificity observed for 
the B2t-ELISA between the present study and the assessment performed previously 
[10]. In this previous study, the serum of 102 Spanish CE patients was analyzed, and a 
sensitivity of 91.2% was obtained with the B2t-ELISA. When the new 2B2t antigen was 
tested using the serum of these 102 patients, a sensitivity of 94.1% was obtained (data 
not shown). Unfortunately, the clinical data available from these patients was scarce. 
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Thus, this higher sensitivity cannot be attributed to specific variables. Similarly, the 
results obtained by other authors using the recombinant antigen B2 for the detection of 
specific IgG in ELISA show highly variable sensitivities, ranging from 45% to 93% [9]. 
From these studies, the sensitivities reported by Rott et al. [23] and Virginio et al. [24] 
are the most similar to the sensitivity found here for the B2t and 2B2t recombinant 
antigens. Unfortunately, further comparison between our results and those obtained in 
these studies is difficult, as previously discussed [10], for a number of reasons, among 
which missing clinical information on the patients used by these authors. Nevertheless, 
these differences indicate the need to reach a consensus to determine the variables to be 
checked when using a serodiagnostic tool for CE. In addition, it is best to use the same 
samples to compare different serological tools [25]. Short of this, there are few chances 
that a better test to detect specific antibodies in CE patients, which could replace the 
very variable and clearly improvable tests based on the use of native antigens, can be 
developed. 
In spite of its limititations, to our knowledge this is the first attempt to take into account 
some of the variables of the extremely complex clinical presentation of human CE [26] 
in the evaluation of several serological tests. T We also show that the performance of a 
serological test  with a defined and specific recombinant antigen can be improved by 
using two units of that antigen in a tandem construct. 
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Figure Legends 
Figure 1. Cloning and production of the B2t (1), 2B2t (2), 4B2t (3) and 8B2t (4) 
recombinant proteins. (A) 1% agarose gel stained with ethidium bromide and (B) 15% 
acrylamide gel stained with Comassie blue, showing the polynucleotides and purified 
recombinant proteins. The molecular weights are indicated in base pairs (A) and 
kilodaltons (B): (1) B2t 213 pb, 8.3 kDa; (2) 2B2t, 446 pb, 16.9 kDa; (3) 4B2t, 874 pb, 
31.3 kDa and (4) 8B2t, 1,738 pb, 60.1 kDa. In (B), 10 l of the supernatant of each 
recombinant protein purified from 1 litre of culture was loaded to compare the final 
concentration of each recombinant protein obtained from the same volume of culture. 
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Table 1. Characteristics of the CE patients from Peru 
CE diagnosis 
Surgery 134 (72.0%) 
Imaging 52 (28.0%) 
Gender 
Male 85 (45.7%) 
Female 101 (54.3%) 
Number of cysts 
Single 108 (58.1%) 
Multiple 78 (41.9%) 
Cyst localisation 
Liver 65 (34.9%) 
Lung 86 (46.2%) 
Liver plus lung 24 (12.9%) 
Other 11 (6.0%) 
Cyst classification* 
CE1 44 (49.4%) 
CE2 22 (24.7%) 
CE3 8 (9.0%) 
CE4 2 (2.2%) 
NS 13 (14.7%) 
Complicated CE# 
No 87 (46.8%) 
Yes 98 (52.7%) 
NS 1 (0.5%) 
First CE 
Yes 20 (10.7%) 
No 166 (89.3%) 
Serum collection 
Before treatment 129 (69.3%) 
After treatment 57 (30.7%) 
 
Data are shown as total number and percentage (%) for each subgroup. * For liver cysts 
only, according to the WHO classification (2003). #According to Beggs (1985). NS: not 
stated. 
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Table 2. Comparative analysis of the diagnostic performance of four different antigens in ELISA. 
 CE Confirmed cases, n=54 (Sensitivity) 
 Overall (n=54) B2t negative (n=12) B2t positive (n=42) 
 
Healthy donors, n=49 (Specificity)
HF 44 (81.5%*) 4 (33%) 40 (95.2%) 46 (93.9%) 
B2t 42 (77.8%*) 0 (0%) 42 (100%) 47 (95.9%) 
2B2t 50 (92.6%) 9 (75%) 41 (97.6%) 47 (95.9%) 
4B2t 43 (79.6%*) 3 (25%) 40 (95.2%) 39 (79.6%*) 
 
The antigens tested were: hydatid fluid (HF), B2t, 2B2t and 4B2t recombinant proteins. IgG specific antibodies were investigated in patients with 
cystic echinococccosis (CE) and healthy donors. n=number of samples. *indicates significant differences between the HF, B2t or 4B2t and 2B2t-
ELISA. 
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Table 3. Sensitivity, specificity and cross-reactivity of four different diagnostic tools. 
 HF-ELISA B2t-ELISA 2B2t-ELISA IHA 
CE Confirmed cases, n=186 (Sensitivity) 155 (83.3%*) 147 (79.0%*) 163 (87.6%) 65 (34.9%*) 
Healthy donors, n=110 (Specificity) 5 (95.4%*) 1 (99.1%) 1 (99.1%) 0 (100%) 
Cross Reactions (n=174)     
AE (n=57) 57 (100%)  7 (12.3%) 10 (17.5%) 24 (42.1%) 
NCC Mexico (n=13) 7 (53.8%)  1 (7.7%) 0 (0%) 0 (0%) 
NCC Peru (n=57) 22 (38.6%)  14 (24.6%) 21 (36,8%) 1 (1.7%) 
Taeniasis Peru (n=11) 4 (36.4%)  1 (9.1%) 2 (18.2%) 0 (0%) 
Hepatitis (n=36) 0 (0%)  1 (2.8%) 1 (2.8%) 1 (2.8%) 
Overall cross-reactions (n=174) 90 (51.7%*) 24 (13.8%*) 34 (19.5%) 26 (14.9%*) 
 
The diagnostic performance of the tools B2t-, 2B2t- and hydatid fluid (HF)-ELISA, and a commercial indirect haemagglutination test (IHA), 
were compared using a panel of sera from cystic echinoccocosis (CE) patients, healthy donors and patients with other diseases (see below). The 
results are shown as the number of positive results against the different tools and the corresponding sensitivity, specificity and cross-reactivity for 
each group. Under “Cross Reactions”: AE: alveolar echinococcosis; NCC MEX: neurocysticercosis Mexico; NCC PERU: neurocysticercosis 
Peru. n: number of samples. *indicates significant differences between the HF-ELISA, B2t-ELISA or IHA tests and the 2B2t-ELISA. 
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Table 4. Influence of clinical variables on the diagnostic sensitivity of four different serodiagnostic tools (chi2). 
  HF-ELISA B2t-ELISA 2B2t-ELISA IHA 
  Positive P Positive P Positive P Positive P 
NUMBER OF CYSTS Single (n=108) 85 (78.7%) 0.046 78 (72.2%) 0.007 90 (83.3%) 0.036 26 (24.1%) 0.000 
 Multiple (n=78) 70 (89.7%)  69 (88.5%)  73 (93.6%)  39 (50.0%)  
CYST LOCALISATION Liver (n=65) 48 (73.8%) 0.060 49 (75.4%) 0.716 57 (87.7%) 0.385 11 (16.9%) 0.002 
 Lung (n=86) 74 (86.0%)  67 (77.9%)  71 (82.5%)  35 (40.7%)  
WHO CLASSIFICATION* CE1 (n=44) 29 (65.9%) 0.012 31 (70.4%) 0.078 39 (88.6%) 1.000 6 (13.6%) 0.032 
 CE2 to CE4 (n=32) 29 (90.6%)  28 (87.5%)  29 (90.6%)  11 (34.4%)  
COMPLICATIONS No (n=87) 65 (74.7%) 0.003 65 (74.7%) 0.186 74 (85.0%) 0.330 18 (20.7%) 0.000 
 Yes (n=98) 89 (90.8%)  81 (82.6%)  88 (89.8%)  46 (46.9%)  
FIRST CE Yes (n=20) 20 (100%) 0.028 17 (85.0%) 0.771 19 (95.0%) 0.476 10 (50.0%) 0.135 
 No (n=166) 135 (81.3%)  130 (78.3%)  144 (86.7%)  55 (33.1%)  
SERUM COLLECTION Before tr. (n=129) 100 (77.5%) 0.001 96 (74.4%) 0.020 111 (86.0%) 0.322 35 (27.1%) 0.001 
 After tr. (n=57) 55 (96.5%)  51 (89.5%)  52 (91.2%)  30 (52.6%)  
 
The diagnostic sensitivity of hydatid fluid (HF)-, B2t- and 2B2t-ELISA, and a commercial IHA kit were compared regarding different clinical 
variables in a panel of cystic echinococcosis patients. Differences are considered significant if P≤0.050 (in bold). The results are shown as the 
number of positive samples and corresponding sensitivity (%) against the different antigens.* refers to liver cysts only. tr : treatment. 
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Table 5. Influence of defined clinical variables on the results of four different diagnostic tools (logistic regression). 
  HF-ELISA B2t-ELISA 2B2t-ELISA IHA 
  B-OR (IC) M-OR (IC) B-OR (IC) M-OR (IC) B-OR (IC) M-OR (IC) B-OR (IC) M-OR (IC) 
NUMBER OF CYSTS Single 1 -- 1 1 1 1 1 1 
 Multiple 2.4 (1.0-5.6) -- 2.9 (1.3-6.6) 2.7 (1.2-6.2) 2.92 (1.03-8.24) 2.7 (0.9-7.7) 3.1 (1.7-5.9) 3.0 (1.5-5.9) 
CYST LOCALISATION Liver 1 -- 1 -- 1 -- 1 1 
 Lung 2.2 (1.0-5.0) -- 1.1 (0.5-2.5) -- 0.66 (0.26-1.70) -- 3.4 (1.5-7.3) 2.7 (1.1-6.8) 
WHO CLASSIFICATION* CE1 1 1 1 -- 1 -- 1 -- 
 CE2 to CE4 4.0 (1.0-15.5) 6.6 (1.1-38.5) 2.2 (0.6-8.0) -- 1.05 (0.23-4.83) -- 2.2 (0.6-8.2) -- 
COMPLICATIONS No 1 1 1 -- 1 -- 1 1 
 Yes 3.3 (1.4-7.7) 2.4 (1.0-5.8) 1.6 (0.8-3.3) -- 1.55 (0.64-3.73) -- 3.4 (1.8-6.5) 2.9 (1.5-5.9) 
FIRST CE Yes 1 -- 1 -- 1 -- 1 -- 
 No 3.7 (0.0) -- 1.6 (0.4-5.6) -- 2.90 (0.37-22.78) -- 2.0 (0.8-5.1) -- 
SERUM COLLECTION Before tr. 1 1 1 1 1 -- 1 1 
 After tr. 8.0 (1.8-34.7) 6.6 (1.5-29.1) 2.9 (1.1-7.4) 2.6 (1.0-6.7) 1.69 (0.59-4.79) -- 3.0 (1.6-5.7) 2.6 (1.3-5.1) 
 
The association and influence of the clinical variables enumerated in the first column on the sensitivity of the hydatid fluid (HF)-, B2t- and 2B2t-
ELISAs and of a commercial IHA kit was statistically assessed. B-OR: odds ratio in the bivariate, and M-OR in the multivariant regression 
analysis. IC: 95% confidence interval. Statistically significant differences (P≤0.050) are shown in the table (in bold). tr.: treatment. 
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